MORL: An Impact on aHUS Genetics
What’s involved in aHUS genetic testing, and are all labs alike? The answer to the first is quite complex, and no…
TMAs and aHUS illustrated
Here is a most unusual clinical article from earlier this year. In Thrombotic microangiopathies : An Illustrated review the Abou-Ismail Group…
KDIGO – aHUS controversies and consensus
Six years ago, aHUS featured, along with another renal disease MPGN/C3G, in a controversies conference held by KDIGO (Kidney Disease Improving…
Atypical HUS – an Interview with Dr Brad Lewis of Machaon Diagnostics
We’re pleased to feature this interview with Dr Brad Lewis, Medical Director of Machaon Diagnostics. A hematologist with background in biochemistry…
Trial watch 16 -Factor D complement inhibitor.
One of the ways to find out which drugs have a potential for aHUS treatment is to look at trials for…
aHUS Trial Watch 15 ( Iptacopan) update
Global Action featured a new trial for an aHUS treatment iptacopan earlier this year ( CLICK ON IMAGE BELOW) aHUS Trial…
aHUS Day 2022: Awareness Through Togetherness
The 8th international aHUS Awareness Day will occur on 24 September 2022, with this year’s theme as ‘Awareness through Togetherness’. We’re…
Atypical HUS: Listen, Comprehend, Act
It’s been quite an unsettling end to the first half of 2022 within the atypical HUS community, as July 2022 has…
Panoramic view of vittà alta. Bergamo - Italy
Bergamo- A Report on aHUS
11am 23 June 2022, Bergamo,Italy: The long awaited ISN Frontiers meeting about Renal Complement diseases featuring aHUS is about to begin.…
- Go to the previous page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- …
- 82
- Go to the next page